Market Place
Sourcing Support
All News #Library
Biotech
FDA Approves Label Update to Accelerate Thaw Time for Adstiladrin
24 Mar 2026 //
BUSINESSWIRE
Ferring Shares Real-World Data on ADSTILADRIN® Use in Clinics
28 Oct 2025 //
BUSINESSWIRE
Ferring Japan NDA for Nadofaragene Firadenovec Accepted by PMDA
11 Sep 2025 //
BUSINESSWIRE
Ferring ADAPT-1 Trial: Dosing Evidence for Follitropin Delta
02 Jul 2025 //
BUSINESSWIRE
Ferring Opens New Gene Therapy Manufacturing Facility
20 Jun 2025 //
CONTRACTPHARMA
Ferring Reveals New Data with ADSTILADRIN® at JUA Meeting
21 Apr 2025 //
BUSINESSWIRE
Ferring: 75% Response Rate at 3 Months in Japanese NMIBC Trial
21 Apr 2025 //
BUSINESSWIRE
Ferring Pharma & Astellas/Pfizer Alliance to End Bladder Cancer
15 Apr 2025 //
PR NEWSWIRE
Ferring`s record sales driven by Reproductive Medicine & Adstiladrin
09 Apr 2025 //
BUSINESSWIRE
ADSTILADRIN Real-World Data To Be Presented At ASCO GU 2025
12 Feb 2025 //
BUSINESSWIRE
Ferring Progresses Three ADSTILADRIN® Clinical Studies
03 Dec 2024 //
BUSINESSWIRE
Ferring Announces Committee for SI-6603 in Lumbar Disc Herniation
02 Dec 2024 //
BUSINESSWIRE
Ferring cuts ribbon at new gene therapy manufacturing hub
04 Oct 2024 //
FIERCE PHARMA
ADSTILADRIN® demonstrates durable bladder preservation and safety in Phase 3.
06 May 2024 //
BUSINESSWIRE
Ferring, SK Pharmteco Partner For Commercial Gene Therapy Manufacturing
18 Apr 2024 //
BUSINESSWIRE
With SK partnership, Ferring boosts long-term Adstiladrin supply
18 Apr 2024 //
FIERCE PHARMA
Ferring Adds 3 NMIBC Trials With ADSTILADRIN®
16 Apr 2024 //
BUSINESSWIRE
Ferring cautiously rolls out bladder cancer gene therapy
13 Sep 2023 //
FIERCE PHARMA
Royalty Pharma to Pay Potential $500M for Royalties on Ferring’s Gene Therapy
25 Aug 2023 //
BIOSPACE
Ferring Pharmaceuticals Receives U.S. FDA Approval for Gene Therapy ADSTILADRIN
13 Jun 2023 //
BUSINESSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.